Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358097 · ClinicalTrials.gov registry record
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
A clinical trial of Head and Neck Cancer and Human Papilloma Virus, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 33
- Enrollment target
- 1
- Study location
NCT01358097: Completed study of Head and Neck Cancer and Human Papilloma Virus, sponsored by Icahn School of Medicine at Mount Sinai.
NCT01358097 is a study of Head and Neck Cancer and Human Papilloma Virus that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 33 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01358097, a study of Head and Neck Cancer and Human Papilloma Virus, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the role of the immune system in the response of squamous cell cancers of the head and neck to treatment that includes radiation therapy. Current research demonstrates that several natural immune cells and molecules affect the way the body's immune system interacts with a cancerous growth. Some cancers may be related to infection with a virus, such as the Human Papilloma Virus (HPV). Studying the activity of the immune system in head and neck cancers, especially cancers related to HPV infections, can provide valuable information to better understand the body's interaction with cancer cells.
Conditions Studied
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai, Otolaryngology - Head and Neck Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-09 |
What the finished NCT01358097 record still lists
NCT01358097 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (87% lower).
The record links to 4 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01358097 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01358097 about?
NCT01358097 is a clinical study titled "Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy". The purpose of this study is to investigate the role of the immune system in the response of squamous cell cancers of the head and neck to treatment that includes radiation therapy. Current research demonstrates that several natural immune cells and molecules affect the way the body's immune system ...
What is the current status of trial NCT01358097?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2010-10. Estimated completion is 2013-09.
What conditions does trial NCT01358097 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Human Papilloma Virus, Oropharyngeal Cancer, Squamous Cell Cancer.
Who is sponsoring clinical trial NCT01358097?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01358097 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01358097's enrollment target sits among peer trials
33 169th of 250 higher than 79 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3D Specimen Maps for RT Planning
RECRUITING
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck
RECRUITING · NA
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia